Format

Send to

Choose Destination
Sci Transl Med. 2018 Apr 11;10(436). pii: eaao3003. doi: 10.1126/scitranslmed.aao3003.

Dual inhibition of MDMX and MDM2 as a therapeutic strategy in leukemia.

Author information

1
Department of Cell Biology, Albert Einstein College of Medicine, Bronx, NY 10461, USA.
2
Department of Anatomy and Structural Biology, Albert Einstein College of Medicine, Bronx, NY 10461, USA.
3
Ruth L. and David S. Gottesman Institute for Stem Cell Research and Regenerative Medicine, Albert Einstein College of Medicine, Bronx, NY 10461, USA.
4
Aileron Therapeutics, Cambridge, MA 02139, USA.
5
Division of Hemato-Oncology, Department of Medicine (Oncology), Albert Einstein College of Medicine, Bronx, NY 10461, USA.
6
Albert Einstein Cancer Center, Albert Einstein College of Medicine, Bronx, NY 10461, USA.
7
Department of Cell Biology, Albert Einstein College of Medicine, Bronx, NY 10461, USA. ulrich.steidl@einstein.yu.edu.

Abstract

The tumor suppressor p53 is often inactivated via its interaction with endogenous inhibitors mouse double minute 4 homolog (MDM4 or MDMX) or mouse double minute 2 homolog (MDM2), which are frequently overexpressed in patients with acute myeloid leukemia (AML) and other cancers. Pharmacological disruption of both of these interactions has long been sought after as an attractive strategy to fully restore p53-dependent tumor suppressor activity in cancers with wild-type p53. Selective targeting of this pathway has thus far been limited to MDM2-only small-molecule inhibitors, which lack affinity for MDMX. We demonstrate that dual MDMX/MDM2 inhibition with a stapled α-helical peptide (ALRN-6924), which has recently entered phase I clinical testing, produces marked antileukemic effects. ALRN-6924 robustly activates p53-dependent transcription at the single-cell and single-molecule levels and exhibits biochemical and molecular biological on-target activity in leukemia cells in vitro and in vivo. Dual MDMX/MDM2 inhibition by ALRN-6924 inhibits cellular proliferation by inducing cell cycle arrest and apoptosis in cell lines and primary AML patient cells, including leukemic stem cell-enriched populations, and disrupts functional clonogenic and serial replating capacity. Furthermore, ALRN-6924 markedly improves survival in AML xenograft models. Our study provides mechanistic insight to support further testing of ALRN-6924 as a therapeutic approach in AML and other cancers with wild-type p53.

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center